Home / Health / Japan conjugate vaccine market by disease indication and end-user – prediction to 2023 – ResearchAndMarkets.com

Japan conjugate vaccine market by disease indication and end-user – prediction to 2023 – ResearchAndMarkets.com



DUBLIN – (BUSINESS WIRE) – August 16, 2018 – The Report & # 39; Japan Conjugate Vaccine Market (2018-2023) & # 39; has been added to the offer of ResearchAndMarkets.com.

Japan is one of the most prominent markets for conjugated vaccines.

Japan has 84 years one of the highest life expectancies in the world. Currently both PPSV-23 and PCV-13 are available for the elderly to prevent Streptococcus pneumoniae related diseases. Despite the fact that these two vaccines are made available to the elderly, the national immunization program started for older people aged 65 and older, such as on 1 October 2014, is only subsidized with PPSV-23. Japan has often reported a low incidence of meningococcal disease, and therefore the disease is not considered a high priority for health care.

Japan is expected to be a stable market for conjugate vaccines during the prognosis period. A rapidly increasing geriatric population, an increase in consumer awareness, growing disposable income and healthcare expenditures and modernization of the health care infrastructure will stimulate the Japanese market for conjugate vaccines. Japan, with the highest life expectancy of all the other countries in the world, has caused its old population the demand for vaccines for adult conjugates.

Although the health situation in Japan is among the best in the world, there is still a significant gap to be filled with regard to the use of vaccines to prevent serious infections. This gap has major implications for public health, both in Japan and in other countries, since Japan is cited as a source of infectious diseases in countries where these diseases are better controlled by vaccination. There is also a need for an efficient immunization program, due to limited health care resources. Underreporting, lack of awareness and focus on meningococcal disease are some of the biggest threats.

Important topics being discussed

Chapter 1. Summary

Chapter 2. Market overview

Chapter 3. Japan Major Segment Overview – per disease alert

Chapter 4. Overview of Japan's largest segment – by end-user

] Chapter 5. Competitive landscape

GlaxoSmithKlinePfizer Inc.Merck & Co.NovartisSanofi PasteurCSL LimitedBharat BiotechBiological E. LimitedSerum Institute of Japan [19659004] For more information on this report, please visit https://www.researchandmarkets.com/research/9mm7kx / japan-conjugate? w = 4

View the source version at businesswire.com:https://www.businesswire.com/ nieuws / home / 20180816005493 / en /

CONTACT: ResearchAndMarkets.com

Laura Wood , Senior Manager

press@researchandmarkets.com

For EST Office hours Call 1-917-300-0470

For US / CAN free call 1-800-526-8630

For GMT Office Hou rs Call + 353-1-416-8900 [19659004] Related Topics: Vaccines

KEYWORD: ASIA PACIFIC JAPAN

KEYWORD IN INDUSTRY: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018. [19659004] PUB: 08/16/2018 11 : 57 AM / DISC: 16-08-2018 11:57

http://www.businesswire.com/news/home/20180816005493/en

Copyright Company Wire 2018.


Source link

Leave a Reply